JP2022533981A5 - - Google Patents

Info

Publication number
JP2022533981A5
JP2022533981A5 JP2021568760A JP2021568760A JP2022533981A5 JP 2022533981 A5 JP2022533981 A5 JP 2022533981A5 JP 2021568760 A JP2021568760 A JP 2021568760A JP 2021568760 A JP2021568760 A JP 2021568760A JP 2022533981 A5 JP2022533981 A5 JP 2022533981A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
compound
formula
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021568760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533981A (ja
JP7568651B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/054755 external-priority patent/WO2020234782A1/en
Publication of JP2022533981A publication Critical patent/JP2022533981A/ja
Publication of JP2022533981A5 publication Critical patent/JP2022533981A5/ja
Priority to JP2024139784A priority Critical patent/JP2024178168A/ja
Application granted granted Critical
Publication of JP7568651B2 publication Critical patent/JP7568651B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021568760A 2019-05-23 2020-05-20 ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法 Active JP7568651B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024139784A JP2024178168A (ja) 2019-05-23 2024-08-21 ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851996P 2019-05-23 2019-05-23
US62/851,996 2019-05-23
PCT/IB2020/054755 WO2020234782A1 (en) 2019-05-23 2020-05-20 Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024139784A Division JP2024178168A (ja) 2019-05-23 2024-08-21 ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法

Publications (3)

Publication Number Publication Date
JP2022533981A JP2022533981A (ja) 2022-07-27
JP2022533981A5 true JP2022533981A5 (cg-RX-API-DMAC7.html) 2023-05-26
JP7568651B2 JP7568651B2 (ja) 2024-10-16

Family

ID=70918751

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568760A Active JP7568651B2 (ja) 2019-05-23 2020-05-20 ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法
JP2024139784A Pending JP2024178168A (ja) 2019-05-23 2024-08-21 ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024139784A Pending JP2024178168A (ja) 2019-05-23 2024-08-21 ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法

Country Status (22)

Country Link
US (2) US12419889B2 (cg-RX-API-DMAC7.html)
EP (2) EP4599894A3 (cg-RX-API-DMAC7.html)
JP (2) JP7568651B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220012281A (cg-RX-API-DMAC7.html)
CN (1) CN113795255A (cg-RX-API-DMAC7.html)
AU (2) AU2020280272B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021022602A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138081A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003032A1 (cg-RX-API-DMAC7.html)
DK (1) DK3972604T3 (cg-RX-API-DMAC7.html)
ES (1) ES3039974T3 (cg-RX-API-DMAC7.html)
FI (1) FI3972604T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251001T1 (cg-RX-API-DMAC7.html)
IL (1) IL286983B2 (cg-RX-API-DMAC7.html)
LT (1) LT3972604T (cg-RX-API-DMAC7.html)
MX (2) MX2021013942A (cg-RX-API-DMAC7.html)
PL (1) PL3972604T3 (cg-RX-API-DMAC7.html)
PT (1) PT3972604T (cg-RX-API-DMAC7.html)
RS (1) RS67141B1 (cg-RX-API-DMAC7.html)
SI (1) SI3972604T1 (cg-RX-API-DMAC7.html)
TW (1) TWI868139B (cg-RX-API-DMAC7.html)
WO (1) WO2020234782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3972604T3 (fi) * 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
CA3239276A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用lou064治療化膿性汗腺炎之方法
KR102834740B1 (ko) * 2023-04-10 2025-07-17 아주대학교산학협력단 Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물
WO2024235163A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 Btk抑制剂的用途和单剂量药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200924781A (en) 2007-09-14 2009-06-16 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2016079669A1 (en) 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
FI3972604T3 (fi) 2019-05-23 2025-09-01 Novartis Ag Brutonin tyrosiinikinaasin estäjä käytettäväksi kroonisen spontaanin urtikarian hoidossa

Similar Documents

Publication Publication Date Title
EP4322942B1 (en) Combination comprising everolimus and amcenestrant
JP2001509173A (ja) 胃腸リパーゼ阻害剤の使用
US12042483B2 (en) Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
TW202011965A (zh) 嗜中性球彈性蛋白酶抑制劑在肝病中之用途
WO2019046287A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B
EP0708644A4 (en) TREATMENT OF -i INFECTION (CRYPTOCOCCUS NEOFORMANS)
KR20240032789A (ko) 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물
EP2808018B1 (en) Therapeutic agent for diabetes
TW202116297A (zh) 組合療法之方法、組成物與套組
TWI464147B (zh) 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
CN1203861C (zh) 含有人参皂甙Rb1的脑血管再生/再造促进剂和继发性神经组织变性抑制剂
JP4609877B2 (ja) 慢性拒絶反応抑制剤
US6090775A (en) Treatment of neurological conditions by an interleukin-1 inhibiting compound
TWI411435B (zh) 4-環丙基甲氧基-n-(3,5-二氯-1-氧離子基吡啶-4-基)-5-(甲氧基)吡啶-2-甲醯胺於治療脊髓創傷之用途
CN116115760A (zh) Eed抑制剂在制备治疗神经免疫性疾病药物中的应用
CN116650490B (zh) 化合物mt-1207在降低尿酸方面的应用
US20060135494A1 (en) Methods of treating injuries of the nervous system associated with hemorrhage
JP2003522121A (ja) 多発性硬化症の処置のためのリルゾールの使用
WO2023203022A1 (en) Treatment of neutrophilic dermatoses
US9248118B2 (en) Compositions and method for treatment of ischemic neuronal reperfusion injury
EP3558378A1 (en) Low dose drug combinations for use in preventing and treating neuronal damage
CA2684171C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
JP2023518430A (ja) 感染症の治療におけるブシラミンの使用
CN1108532A (zh) 皮肤癌治疗
EP4552642A1 (en) Agent for reducing blood myostatin level